Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
721-740 of 1,738 trials

Early Breast Cancer: Abemaciclib and Giredestrant Study

We are investigating the safety and effectiveness of two medications for patients with early-stage, hormone-sensitive breast cancer before surgery. The goal is to see if this treatment can help reduce tumor size and improve outcomes.

Early Breast Cancer (ER-positive, HER2-negative)6-12 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

High-Grade Soft Tissue Sarcoma: Ifosfamide and Doxorubicin Study

We are studying a combination of chemotherapy drugs for patients with localized high-grade soft tissue sarcoma. The goal is to see how well this treatment works and to understand its safety and impact on quality of life.

Soft Tissue SarcomaEfficacy phase (II)No PlaceboStandard MedicinesOncology

Acute Agitation: Comparing New Medications

We are studying how well sublingual dexmedetomidine and buccal midazolam work for calming patients in emergency settings compared to oral lorazepam. We also want to know about their safety and how satisfied patients feel with these treatments.

Acute Agitation>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesPsychiatry

Advanced Lung Cancer: STX-241 Study

We are testing a new oral anticancer drug, STX-241, for patients with advanced non-small cell lung cancer resistant to standard treatments. The goal is to evaluate its safety and potential effectiveness.

Metastatic Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Multiple Sclerosis: Stem Cell Treatment Study

We are investigating whether a new stem cell treatment can help regenerate nerve function in patients with progressive multiple sclerosis. The study will also assess safety and other health measures.

Multiple Sclerosis>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurology

BCR/ABL1-Like Acute Lymphoblastic Leukemia: Ponatinib and Chemotherapy

We are studying a new treatment combining ponatinib and chemotherapy for adults with BCR/ABL1-like acute lymphoblastic leukemia. The aim is to improve remission rates and monitor disease response over time.

Acute Lymphoblastic LeukemiaEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Rare Cancers: Dendritic Cell Vaccine Study

We are testing a new vaccine made from patients' own tumor cells for those with resected stage IV neuroendocrine tumors and soft tissue sarcomas. The study aims to evaluate safety and how well the immune system responds to the treatment.

Soft Tissue SarcomaNeuroendocrine Tumors>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Rheumatoid Arthritis: FBL-MTX Injection Study

We are investigating a new injectable treatment for moderate-to-severe rheumatoid arthritis in patients who haven't used DMARDs or have had issues with oral methotrexate. The study will evaluate how well it works and its safety.

Rheumatoid Arthritis3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineRheumatology

Behçet's Syndrome: Steroids Plus Anticoagulants Study

We are investigating whether adding anticoagulants to steroid therapy helps reduce the risk of deep venous thrombosis relapse in people with Behçet's syndrome. This study will also look at safety and quality of life.

Behcet's Syndrome>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesHematologyInternal MedicineRheumatology

Solid Tumors: E7386 with Other Anticancer Drugs

We are studying the safety and effectiveness of E7386 combined with other anticancer treatments for patients with solid tumors. This trial aims to find the best dose and assess how well it works compared to standard therapies.

Liver Cancer (Hepatocellular Carcinoma)Colorectal CancerEndometrial CancerSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Oral Midazolam for Patients Refusing Care

We are studying whether oral midazolam can help older patients with moderate to severe cognitive disorders accept necessary care. The trial also looks at its safety and the satisfaction of healthcare providers.

Cognitive Issues and Agitation in the Elderly>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyPsychiatry

Prurigo Nodularis: Barzolvolimab Study

We are testing a new medication, barzolvolimab, for people with prurigo nodularis to see if it helps reduce itching and improve skin lesions. The study will also look at the safety of this treatment and its effects on quality of life.

Prurigo Nodularis6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesAllergologyDermatology

Sickle Cell Disease: BMS-986470 Study

We are testing a new medication, BMS-986470, to see if it is safe and well-tolerated in healthy volunteers and people with sickle cell disease. The study aims to find the best dose and evaluate its effects on hemoglobin levels.

Sickle Cell DiseaseSafety phase (I)Efficacy phase (II)Investigational MedicinesHematologyInternal Medicine

Chronic Inflammatory Diseases: Low-Dose Interleukin-2 Therapy

We are studying the safety and effectiveness of low-dose interleukin-2 therapy for patients with conditions like Pemphigus vulgaris and Mucous Membrane Pemphigoid. This trial aims to see how well this treatment works compared to a placebo.

Primary Sclerosing Cholangitis (PSC)Mucous Membrane PemphigoidPolymyositis/Dermatomyositis3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementDermatologyInfectious DiseasesRheumatology

Gene Therapy for Central Nervous System Cancer

We are exploring a new gene therapy using stem cells for patients with cancer in the central nervous system. This study aims to see if it can improve treatment outcomes for these patients.

GlioblastomaSafety phase (I)Efficacy phase (II)NeurologyOncology

Myotonic Dystrophy Type 1: DYNE-101 Treatment Study

We are evaluating the safety and effects of a new treatment, DYNE-101, for people with Myotonic Dystrophy Type 1. The study aims to see how it impacts muscle health and overall well-being.

Myotonic Dystrophy>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurologyOrthopedics and Traumatology

Mixed Dyslipidemia: RBD5044 Treatment Study

We are testing a new medication, RBD5044, for people with mixed dyslipidemia to see if it improves cholesterol and lipid levels. The study also looks at the safety of this treatment when given as injections.

Mixed Dyslipidemia6-12 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCardiologyInternal Medicine

Cystic Fibrosis: Anakinra Treatment Study

We are testing the safety and effectiveness of anakinra for adults and possibly adolescents with cystic fibrosis. The study aims to see if it improves lung function and quality of life.

Cystic Fibrosis>2 yearsEfficacy phase (II)Standard MedicinesInternal MedicinePulmonology

Severe Diffuse Cutaneous Systemic Sclerosis: Rapcabtagene Autoleucel vs. Rituximab

We are studying a new treatment to see if it works better than rituximab for people with severe diffuse cutaneous systemic sclerosis. The trial will also evaluate the safety of this new therapy.

Systemic Scleroderma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Crigler-Najjar Syndrome: GNT0003 Treatment Study

We are evaluating a new treatment called GNT0003 for adults with severe Crigler-Najjar syndrome who need daily phototherapy. The study aims to see if this treatment is safe and effective for those with pre-existing antibodies.

Crigler-Najjar Syndrome>2 yearsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHepatologyInternal Medicine